- Conditions
- Down Syndrome
- Interventions
- Placebo, Tofacitinib Oral Solution
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 6 Years to 22 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
Location Directory
Clinical trials in Aurora, Colorado
This page shows live ClinicalTrials.gov search results for Aurora, Colorado, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
3415
Shown on this page
12
Local exact-city summaries
3415
Based on exact city/state matches in the local index.
Local exact-city recruiting
736
Live official results below use the broader ClinicalTrials.gov location search.
Showing 1–12 of 3,415 matching trials in Aurora, CO.
Indexed local directory records.
Top conditions in local exact-city summaries
Top sponsors in local exact-city summaries
Top therapies in local exact-city summaries
Indexed official records
Open in full search- Conditions
- Locally Advanced Cervical Adenocarcinoma
- Interventions
- Biospecimen Collection, Brachytherapy, Carboplatin, Chest Radiography, Cisplatin, Computed Tomography, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Positron Emission Tomography
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 243
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 193 more
- Conditions
- ANCA Associated Vasculitis (AAV)
- Interventions
- Active Comparator, Glucocorticoids, Rapcabtagene autoleucel
- Other · Drug · Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Jacksonville, Florida • Chicago, Illinois + 8 more
- Conditions
- Untreated Follicular Lymphoma
- Interventions
- Surovatamig, R-CHOP, R-CVP, BR
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 1,018 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 51
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 45 more
- Conditions
- Gram-negative Bacterial Infection
- Interventions
- Part A: ATM-AVI Single Dose, Cohorts 1-4, Part B: Multiple-dose ATM-AVI, Cohorts 1-4
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- Up to 39 Weeks
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 13
- States / cities
- Orange, California • Aurora, Colorado • Indianapolis, Indiana + 5 more
- Conditions
- Diabetes Mellitus, Type 2, Metabolic Syndrome, PreDiabetes
- Interventions
- The Cleerly CAD Staging System
- Device
- Lead sponsor
- Cleerly, Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 7,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 124
- States / cities
- Chandler, Arizona • Scottsdale, Arizona • Sun City, Arizona + 99 more
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
- Interventions
- Biospecimen Collection, Cyclophosphamide, Doxorubicin, Durvalumab, Genetic Testing, Mammography, Paclitaxel, Quality-of-Life Assessment
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 3,680 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 534
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 411 more
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
- Interventions
- Biospecimen Collection, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration, Relatlimab, cfDNA or ctDNA Measurement
- Procedure · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 992 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 487
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 367 more
- Conditions
- Adult T-cell Leukemia/Lymphoma, Aggressive NK-cell Leukemia, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Angioimmunoblastic T-cell Lymphoma, Breast Implant-Associated Anaplastic Large Cell Lymphoma, Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form, Chronic Lymphoproliferative Disorder of NK Cells, Enteropathy-associated T-cell Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Follicular T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract, Intestinal T-Cell Lymphoma, Not Otherwise Specified, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Mycosis Fungoides, NK-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma, Primary Cutaneous Anaplastic Large Cell Lymphoma, Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma, Primary Cutaneous T-cell Lymphoma, Sezary Syndrome, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood, Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder), T-cell Large Granular Lymphocytic Leukemia, T-cell Lymphoma, T-cell Prolymphocytic Leukemia
- Interventions
- Optional Blood Sample and Nail Sample
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 26
- States / cities
- Duarte, California • San Diego, California • San Francisco, California + 20 more
- Conditions
- Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, FDG-Positron Emission Tomography and Computed Tomography Scan, Lumbar Puncture, Multigated Acquisition Scan, Tovorafenib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 180 Days to 22 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 104
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 82 more
- Conditions
- Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor
- Interventions
- Biospecimen Collection, Carboplatin, Computed Tomography, Echocardiography Test, High-Dose-Rate Vaginal Cuff Brachytherapy, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Multigated Acquisition Scan, Paclitaxel, Survey Administration, Trastuzumab/Hyaluronidase-oysk
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 403
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 304 more
- Conditions
- Pediatric Migraine
- Interventions
- Matching placebo, Rimegepant/BHV3000
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 2,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 171
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 107 more